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Current therapeutic strategies to treat neurodegenerative diseases, such as alpha-synucleinopathies, aim at enhancing the amount
of drug reaching the brain. Methods proposed, such as intranasal administration, should be able to bypass the blood brain barrier
(BBB) and even when directly intracerebrally injected they could require a carrier to enhance local release of drugs. We have
investigated the effect of a model synthetic hydrogel to be used as drug carrier on the amount of alpha-synuclein aggregates in cells
in culture. The results indicated that alpha-synuclein aggregation was affected by the synthetic polymer, suggesting the need for
testing the effect of any used material on the pathological process before its application as drug carrier.
1. Introduction
Neurodegenerative diseases, such as alpha-synucleinopa-
thies, affect nerve cells function, leading to their death, dis-
ruption of neuronal network, and development of disease
[1]. Alpha-synucleinopathies such as Parkinson’s disease and
Dementiawith Lewy bodies are characterized by the presence
of intracellular alpha-synuclein filamentous aggregates in
degenerating cells in the form of Lewy bodies and Lewy
neurites, while in multiple system atrophy they form glial
cytoplasmic inclusions [1]. It is now clear that alpha-synuclein
aggregates spread from one cell to the other, contributing to
the progressive development of pathology.
Although intensively studied for many years, no treat-
ment is currently available to stop progression of the
neurodegenerative process. The approved pharmacological
treatments available only provide symptomatic relief and a
reduction in disease progression. One of the main factors
affecting drug efficacy and utilization is the inability to reach
the brain at a therapeutic concentration. To overcome this
limitation, invasive treatments such as intracranial injection
of hydrogels for drug delivery have been developed [2].
The use of a bioresorbable hydrogel loaded with drugs or
engineered cells to achieve a direct drug delivery to the
brain would ideally provide continuous drug supply at a
clinically relevant concentration without the need of surgical
intervention for its removal. Synthetic and natural polymers
have been therefore investigated for intracerebral release
of anti-inflammatory and neurotrophic factors leading to
increased neuroprotection [2–4].
As an alternative to intracerebral delivery, the nasal
route of administration has recently gained great interest
for the treatment of neurodegenerative diseases, since it
provides a noninvasive method for rapid drug adsorption
bypassing the obstacle created by the blood brain barrier
(BBB) [5]. The efficacy of the nasal drug uptake, compared
to intraperitoneal route for example, has been demonstrated
using different biomolecules, with the results showing that
the amount of molecules reaching the brain is more than
5 times higher with the intranasal compared to intraperi-
toneal delivery [6]. Different formulations of polymers have
been tested to maximize the drug uptake from the nasal
cavity to the brain. Among them, mucoadhesive hydrogels
have been shown to prolong the contact time between the
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drug and the nasal mucosa. The drug bioavailability is
consequently increased, reducing the number of adminis-
trations needed to achieve the targeted therapeutic effect
[7].
Synthetic, amphiphilic multiblock copolymers with ther-
mosensitive behavior have been widely applied as injectable
drug delivery systems [8–10]. Among them, Poloxamers,
a family of triblock poly(ethylene glycol)-poly(propylene
oxide)-poly(ethylene glycol) (PEG-PPO-PEG) hydrogels,
have been extensively used [8]. Pluronic F-127 is one of
the more widely applied Poloxamers in the biomedical field
[11]. Chen et al. have recently developed a Pluronic F-127
based gel for the nasal administration of curcumin to the
brain, demonstrating superior drug uptake compared to the
intravenous administration route [12]. Strappe et al. have
developed an injectable Pluronic F-127 gel for the intracranial
delivery of a lentiviral vector to the brain [13].
However, despite being widely proposed and sometimes
used, hydrogels for the intracerebral and nasal administration
of drugs to the brain have not been adequately characterized
as the presence of hydrogels and their dissolution products
could interfere with the treated pathology.
In intracerebral application, hydrogels are in direct con-
tact with the brain tissue and may interact with cells, causing
unwanted side effects affecting cell behavior. In intranasal
applications, the permeability of the nasalmucosa to hydrogel
molecules has not yet been studied; this will be relevant in
order to exclude the possibility that lower molecular weight
molecules may cross the nasal barrier and reach the brain,
with possible side effects.
Up to date, studies analyzing the influence of polymeric
drug carriers on neurodegenerative pathologies have not
been reported, and experimental methods for such an analy-
sis are consequently missing.
In this work, we investigate the effect of PEG-PPO-PEG
hydrogels on alpha-synuclein aggregation using an in vitro
cellular model that was previously developed [14], where
human neuroblastoma cells are infectedwith alpha-synuclein
filamentous aggregates produced by proteinmisfolding cyclic
amplification (PMCA) [14].
Results show that the presence of PEG-PPO-PEG
increases the formation of alpha-synuclein fibrillary aggre-
gates, which could induce unwanted contribution to pathol-
ogy progression. These data support the need to investigate
the effect of hydrogels in the pathological process before their
use for drug delivery to the brain.
2. Materials and Methods
2.1. PEG-PPO-PEG Hydrogel Preparation. A PEG-PPO-PEG
solution was prepared by dissolving 200mg of Pluronic F-127
(Sigma-Aldrich) in 1ml of Roswell Park Memorial Institute
(RPMI) medium (Gibco) containing 10% fetal bovine serum
(FBS, Invitrogen), 1% of penicillin/streptomycin (Gibco), and
1% L-Glutamine (Gibco) at 4∘C and then adding 100 𝜇l of
Pluronic 68 10% solution (Sigma Aldrich). The hydrogel
was obtained by pouring 750 𝜇l of the final solution in
a silicon mold which was left at 37∘C for 30 minutes to
achieve complete gelation [12].Then, a volume of 1.5ml RPMI
medium was added. After 24 h, the supernatant containing
PEG-PPO-PEG hydrogel dissolution products was collected
and used for in vitro cell testing.
2.2. Cytotoxicity Assay: 3-(4,5-Dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium Bromide (MTT) Assay. MTT assay was
performed to evaluate hydrogel cytotoxicity using human
neuroblastoma cell line SH-SY5Y (ATCCCRL. 2266). SH-
SY5Y cells were cultured on a 96-multiwell plate at a cell
density of 8× 104 cells/well for 24 h to reach confluence.Then,
the culture medium was removed and substituted with the
supernatant collected from the PEG-PPO-PEG hydrogel (as
prepared as described in par. 2.1) at 1 : 1 and 1 : 5 v : v dilution.
Positive control (CTRL+) was obtained inducing complete
cell death by adding 20% dimethyl sulfoxide (DMSO, Sigma-
Aldrich) to medium, while normal medium was used for
negative control (CTRL−). After 24 h incubation, the super-
natant was carefully removed and the MTT assay was per-
formed following supplier’s instructions. Briefly, a volume of
100 𝜇l MTT solution (Sigma-Aldrich, 5mg/ml in phosphate-
buffered saline (PBS)) was added in eachwell and the cultures
were incubated for 3 h. Then, MTT solution was removed
and 100 𝜇l DMSO was added to each well and gently mixed
to dissolve the formazan crystals. Absorbance was measured
using an UV-Vis plate reader (Tecan Infinite M200PRO)
at 570 nm wavelength. Cell viability was calculated as a
percentage value compared to CTRL+. Six samples for each
condition were used and experiments were performed three
times. GraphPad Prism software was used for one-way or
two-way analysis of variance (ANOVA). ∗𝑝 < 0.05 was
considered statistically significant.
2.3. Effect of PEG-PPO-PEG Hydrogel on Alpha-Synuclein
Fibrils (𝛼FF) Aggregation. SH-SY5Y cells were cultured on
glass coverslip in a 24-multiwell plate at a cell density of 2 ×
104 cells/well for 24 h prior to infection. Then, fresh media
containing 70 nM (a 1:1000 dilution from the 70 uM stock) of
𝛼FF, prepared following PMCA protocol developed by Herva
et al. [14], were added and, at the same time, hydrogel super-
natant at 1 : 5 v : v dilution was supplied to the infected cells.
After 5 days, cells were fixed with a 4% paraformaldehyde
solution (Sigma-Aldrich), permeabilized using 0.003%Triton
(Sigma-Aldrich), and then stained using 4󸀠,6-diamidino-2-
phenylindole (DAPI, Sigma-Aldrich) 1 : 10000 diluted in PBS
and pentameric formof formyl thiophene acetic acid (pFTAA
kindly provided by Klingstedt et al. [15]) 1 : 10000 diluted in
PBS for cell nuclei and 𝛼FF detection, respectively.
Cells were photographed under a fluorescence micro-
scope (Leica CTR4000). Six images for sample were taken
at 20x magnification and the experiment was repeated three
times. Cell nuclei were counted using ImageJ to measure the
number of adhered cells, while the amount of cells possessing
𝛼FF aggregates (𝛼FF-cells) was quantified, counting the
number of cells showing at least one green spot using ImageJ.
Data were expressed as the average number of 𝛼FF cells
with respect to the total number of adhered cells for each
image ± standard deviation. Finally, the intensity of green
spots within𝛼FF cells was quantified using ImageJ processing
tools.



























































Figure 1: Viability of SH-SY5Y cells cultured in the presence of the
extracts fromPEG-PPO-PEGhydrogel at different dilution ratios (at
1 : 1 and 1 : 5 v : v dilution), compared to positive (culture medium)
and negative (complete cell death induced by adding 20% of DMSO)
controls. Asterisks denote statistically significant difference with
∗𝑝 ≤ 0.05 (ANOVA using GraphPad Prism software).
3. Results
3.1. Cytotoxicity Assay: 3-(4,5-Dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium Bromide (MTT) Assay. To determine the
toxicity of PEG-PPO-PEG, cells were exposed at two different
dilutions (1 : 1 and 1 : 5 v : v dilution) of extracts from the
hydrogels. Figure 1 shows the viability of SH-SY5Y cells
cultured in the presence of the extracts (dissolution prod-
ucts) from PEG-PPO-PEG hydrogels at different dilution
ratios. Data were reported as percentage of negative control
condition (CTRL−), where cells were cultured using normal
medium. A positive control (CTRL+) was also obtained
by adding 20% dimethyl sulfoxide (DMSO, Sigma-Aldrich)
to medium to induce complete cell death. PEG-PPO-PEG
dissolution products showed a good biocompatibility: only
a slight reduction in cell viability (reaching 80% compared
to CTRL−) was observed for nondiluted solutions (dilution
1 : 1), while no significant difference in cell viability was
measured for 1 : 5 dilution (>90%) compared to control
conditions (100%). The 1 : 5 dilution was therefore selected to
test alpha-synuclein fibrils (𝛼FF) aggregation in the presence
of hydrogel dissolution products.
3.2. Effect of PEG-PPO-PEG Hydrogel on Alpha-Synuclein
Fibrils (𝛼FF) Aggregation. The influence of hydrogel disso-
lution products on 𝛼FF accumulation by the SH-SY5Y cells
was measured as a parameter to evaluate the interaction of
drug carriers with pathology progression. Results showed
that the presence of PEG-PPO-PEG dissolution products
caused an increase in the amount of SH-SY5Y cells possessing
alpha-synuclein fibrils aggregates (𝛼FF cells) compared to
the control (Figure 2). Then, each image was processed to
quantify the green intensity ascribed to 𝛼FF fibrils within
𝛼FF cells. This analysis shows green intensity inside 𝛼FF cells
from 4 to 10 times higher when 𝛼FF cells were cultured with
media containing both 𝛼FF and PEG-PPO-PEG dissolution
products compared to cells cultured inmedia containing 𝛼FF
only (Figure 3), confirming the increase in the amount of


















Figure 2: Histograms report the percentage of SH-SY5Y cells pos-
sessing 𝛼FF fibrils (𝛼FF cells) with respect to SH-SY5Y cells adhered
when SH-SY5Y cells were cultured in normal media (naı̈ve), in
media containing 1 nM of 𝛼FF (𝛼FF), and in media containing
both 1 nM of 𝛼FF and hydrogel supernatant at 1 : 5 dilution (𝛼FF
hydrogel).
products. Furthermore, when cells were cultured in the pres-
ence of both 𝛼FF and PEG-PPO-PEG dissolution products,
cell clusters formed (Figures 3(e) and 3(f)), foreseeing an
accelerated fibrils propagation within closer cells.
4. Conclusion
Drug carriers represent an effective tool to increase the
ability of drugs to reach the target tissues. In the last years,
the use of both intracerebrally injected and intranasally
administered hydrogels for drug delivery to the brain has
paved the way for the development of innovative therapies
for the treatment of neurodegenerative diseases. When using
intracerebrally administered hydrogels, cells are in direct
contact with the carrier material and its dissolution products,
while in the case of intranasal administration, only an amount
of low molecular weight hydrogel dissolution products may
pass through the nasal mucosa reaching the brain cells.
However, in both cases, the effect of hydrogel dissolution
products on the pathology progression requires investigation,
particularly in diseases with protein aggregation like alpha-
synucleinopathies, where it is known that protein aggregates
spread from one cell to another. In this study, an in vitro
method was used to analyze the influence of PEG-PPO-
PEG hydrogel dissolution products on infection of SH-
SY5Y cells with 𝛼FF. The experiments showed a relevant
increase in the amount of SH-SY5Y cells possessing 𝛼FF
fibrils (𝛼FF cells) per image and an increase of 𝛼FF fibrils
inside 𝛼FF cells, when cells were infected and cultured in the
presence of hydrogel dissolution products. The ability of this
hydrogel to enhance 𝛼FF aggregates could strongly affect the
pathology progression, limiting the efficacy of the treatment
inducing an unwanted contribution to aggregates formation.
These findings highlight the importance of a more detailed
characterization of the polymer carriers used for intracerebral
or nasal drug delivery before exploring potential treatments
for neurodegenerative diseases. Future work will need to


































Figure 3: Fluorescence microscopy representative images of SH-SY5Y cells after 5 days of culture in normal media ((a) and (b)), in media
containing 1 nM of 𝛼FF ((c) and (d)), and in media containing both 1 nM of 𝛼FF and hydrogel supernatant ((e) and (f)). Cell nuclei are
reported in blue (DAPI staining) and 𝛼FF fibrils in green (PFTA staining). Bars: 50 𝜇m. (g) Green intensity inside 𝛼FF cells. Data are reported
as percentage compared to green intensity inside 𝛼FF cells when SH-SY5Y cells were cultured with media containing 𝛼FF only.
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be performed to determine in vivo whether the amount of
hydrogel dissolution products that reach the brain is also pro-
moting increased alpha-synuclein aggregation and whether
there is a difference between intracerebral and intranasal
injections. The development of smart polymers able to avoid
unwanted effects that could affect the treatment outcomes is
a key strategy to open the way for novel therapies based on
drug delivery systems for neurodegenerative diseases.
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